Michael Rome, PhD


Dr. Michael Rome joined Foresite Capital in 2016 and is active in the firm’s public and private market investments. Michael has experience investing across diverse therapeutic areas and has board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, Pharvaris, LifeMine Therapeutics and Kinnate Biopharma. Prior to Foresite Capital, he was an equity analyst at DAFNA Capital Management, a long-short healthcare hedge fund, where he analyzed fund positions and formulated investment ideas in small/mid-cap biotechnology companies.

Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his Ph.D. in Biochemistry from Caltech as an NSF graduate research fellow, and his B.S. in Molecular, Cell and Developmental Biology from UCLA. He has more than 12 years of experience as a research scientist and has authored numerous publications in top-tier biomedical research journals.


  • Experience in both small/mid-cap healthcare investing and early stage drug development.
  • Authored/Co-authored high profile scientific papers (including PNAS, Cell, and Nature SMB) and a selected speaker at scientific conferences.
  • 12 years of experience as a biomedical scientist in biochemistry, microbiology, and neurobiology research laboratories.